AVLN — Avalyn Pharma Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1540171 ·
Last close
$28.08
Market Cap
$1.24B
52W High
$40.17
52W Low
$24.15
ADV30
221,307
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -31,290,000 | -28,935,000 | 425,448,000 | 264,197,000 | 27,102,000 |
| Mar 2026 | 0 | — | -27,909,000 | -26,869,000 | 135,663,000 | 92,310,000 | 399,908,000 |
| Jun 2025 | 0 | — | -21,777,000 | -20,191,000 | — | — | — |
| Mar 2025 | 0 | — | -18,716,000 | -17,503,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-49,166,000
Investing CF
$79,143,000
Financing CF
$14,862,000
CapEx
$-326,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.06
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-292,231,000
Inventory
—
Receivables
$253,000
ST Investments
$30,817,000
EBIT TTM
$-44,274,000
Pretax Income TTM
$-44,372,000
Interest Exp TTM
$98,000
Analysts
4
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -91,292,000 | -85,204,000 | 148,881,000 | 387,537,000 | -238,656,000 | -81,484,000 |
| Dec 2024 | 0 | -57,121,000 | -49,744,000 | 124,519,000 | 299,041,000 | -174,522,000 | -48,368,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.90
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $27.95 · call volume: 10 · put volume: 10Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HROW | HARROW, INC. | $1.24B | $33.07 | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.23B | $34.42 | — |
| OPK | OPKO HEALTH, INC. | $1.22B | $1.64 | — |
| BCAX | Bicara Therapeutics Inc. | $1.27B | $19.21 | — |
| DMRA | Damora Therapeutics, Inc. | $1.28B | $20.66 | — |
News headlines (Yahoo Finance, 1h cache)
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
2026-09-16 20:01 · Yahoo
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
2026-09-08 12:00 · Yahoo
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
2026-08-24 20:01 · Yahoo
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-12 12:00 · Yahoo
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
2026-06-06 02:06 · Yahoo
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-06-03 11:00 · Yahoo
Avalyn to Participate in the Jefferies Global Healthcare Conference
2026-05-27 12:00 · Yahoo
Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey
2026-09-23 09:15 · Yahoo
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
2026-09-21 13:00 · Yahoo
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
2026-09-08 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.